首页> 美国卫生研究院文献>BMC Pharmacology Toxicology >5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter prospective observational study

【2h】

5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter prospective observational study

机译：5-羟基羟基胺-3受体拮抗剂和地塞米松作为化疗诱导的化疗诱导的恶心和呕吐在适用于固体瘤的中等辐射化疗：多中心前瞻性观察性研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Flow chart showing the enrollment of patients

机译：显示患者注册的流程图

著录项

期刊名称 BMC Pharmacology Toxicology
作者
Reiko Matsui; Kenichi Suzuki; Tomomi Takiguchi; Makoto Nishio; Takeshi Koike; Toshinobu Hayashi; Takashi Seto; Yuki Kogure; Naoyuki Nogami; Kimiko Fujiwara; Hiroyasu Kaneda; Tomohiko Harada; Satoru Shimizu; Masashi Kimura; Hirotsugu Kenmotsu; Mototsugu Shimokawa; Koichi Goto;
展开▼
作者单位

展开▼
年(卷),期 2020(-1),-1
年度 2020
页码 -1
总页数 10
原文格式 PDF
正文语种
中图分类药学;
关键词

机译：止吐疗法;化疗诱导的恶心和呕吐（CINV）;中度催吐风险化疗（MEC）;NK-1受体拮抗剂;5-HT3受体拮抗剂;

相似文献

外文文献
中文文献
专利

1. A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting [J] . Hayashi Toshinobu, Shimokawa Mototsugu, Miyoshi Takanori, Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer . 2017,第9期

机译：低催吐风险化疗诱导的恶心和呕吐的危险因素和预防危险因素和预防的前瞻性，观测，多中心研究
2. Risk factors for delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy: a prospective, observational, multicenter study [J] . Toshinobu Hayashi, Mototsugu Shimokawa, Koichi Matsuo, Cancer Management and Research . 2018,第4期

机译：低催吐风险化疗延迟化疗引起的恶心和呕吐的危险因素：一项前瞻性，观察性，多中心研究
3. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy. [J] . Arpornwirat W, Albert I, Hansen V Cancer: A Journal of the American Cancer Society . 2009,第24期

机译：新型神经激肽-1受体拮抗剂casopitant联合恩丹西酮和地塞米松在预防中度致癌化学疗法的癌症患者中预防化疗引起的恶心和呕吐的2期试验结果。
4. A comparison of dosing regimens of the anti-emetic dexamethasone for the prophylaxis treatment of post-operative nausea and vomiting. [D] . Caul, Tina. 2010

机译：止吐地塞米松预防术后恶心和呕吐的给药方案比较。
5. Risk factors for delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy: a prospective observational multicenter study [O] . Toshinobu Hayashi, Mototsugu Shimokawa, Koichi Matsuo, 2018

机译：低催吐风险化疗延迟化疗引起的恶心和呕吐的危险因素：一项前瞻性观察性多中心研究
6. 5-Hydroxytryptamine-3 Receptor Antagonist and Dexamethasone as Prophylaxis for Chemotherapy Induced Nausea and Vomiting during Moderately Emetic Chemotherapy for Solid Tumors: A Multicenter, Prospective, Observational Study [O] . Reiko Matsui, Kenichi Suzuki, Tomomi Takiguchi, 2020

机译：5-羟基羟基胺-3受体拮抗剂和地塞米松作为化疗诱导的化疗诱导恶心和呕吐在适度肿瘤中的中等辐射化疗：多中心，前瞻性，观测研究

5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter prospective observational study

摘要

著录项

相似文献

相关主题

期刊订阅